CVS Health Corporation $CVS Shares Bought by World Investment Advisors

World Investment Advisors lifted its holdings in shares of CVS Health Corporation (NYSE:CVS) by 36.5% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 73,409 shares of the pharmacy operator’s stock after acquiring an additional 19,623 shares during the quarter. World Investment Advisors’ holdings in CVS Health were worth $5,826,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds and other institutional investors have also made changes to their positions in the business. PeakShares LLC acquired a new position in shares of CVS Health during the 4th quarter valued at $40,000. Corient Private Wealth LLC lifted its holdings in shares of CVS Health by 6.1% during the 4th quarter. Corient Private Wealth LLC now owns 397,228 shares of the pharmacy operator’s stock valued at $31,540,000 after acquiring an additional 22,764 shares in the last quarter. Auto Owners Insurance Co lifted its holdings in shares of CVS Health by 8,052.0% during the 4th quarter. Auto Owners Insurance Co now owns 461,161 shares of the pharmacy operator’s stock valued at $3,660,000 after acquiring an additional 455,504 shares in the last quarter. Union Savings Bank acquired a new position in shares of CVS Health during the 4th quarter valued at $184,000. Finally, Bayban acquired a new position in shares of CVS Health during the 4th quarter valued at $64,000. Institutional investors and hedge funds own 80.66% of the company’s stock.

Insider Activity

In other news, EVP Tilak Mandadi sold 69,551 shares of CVS Health stock in a transaction dated Friday, May 8th. The shares were sold at an average price of $89.58, for a total value of $6,230,378.58. Following the completion of the transaction, the executive vice president directly owned 10,133 shares of the company’s stock, valued at approximately $907,714.14. The trade was a 87.28% decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, Director Larry Robbins sold 370,462 shares of CVS Health stock in a transaction dated Thursday, May 21st. The shares were sold at an average price of $93.45, for a total transaction of $34,619,673.90. Following the completion of the transaction, the director directly owned 4,824,799 shares of the company’s stock, valued at $450,877,466.55. This trade represents a 7.13% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders sold a total of 3,441,551 shares of company stock valued at $323,703,977 in the last three months. Insiders own 0.85% of the company’s stock.

CVS Health News Summary

Here are the key news stories impacting CVS Health this week:

• Positive Sentiment: Barclays raised its price target on CVS Health to $106 from $101 and maintained an overweight rating, signaling improved Wall Street confidence in the stock’s upside. Barclays price target raise
• Positive Sentiment: Aetna said its second-generation Claims Assist Manager, an AI-powered claims platform, has cut claims processing time by more than 20% while improving payment accuracy, a potential margin and efficiency tailwind for CVS Health. Aetna AI claims update
• Positive Sentiment: MinuteClinic and Hartford HealthCare expanded primary care access across Connecticut, adding another growth-oriented partnership that could help CVS broaden patient access and utilization. MinuteClinic Hartford HealthCare expansion
• Positive Sentiment: Aetna Better Health of Missouri announced a $175,000 community investment to address food insecurity and safety/wellness supports, reinforcing CVS Health’s Medicaid/community-health positioning. Aetna Missouri community investment
• Neutral Sentiment: CVS Health is also drawing attention for broader analyst commentary, but the article provided did not include a clear new catalyst beyond market discussion. Analyst commentary on CVS Health
• Negative Sentiment: CVS sued Tennessee over a new PBM-pharmacy ownership law, arguing it unlawfully targets out-of-state companies and could force the company to shut pharmacies in the state, creating regulatory and earnings risk. CVS Tennessee lawsuit

CVS Health Stock Performance

CVS Health stock opened at $92.02 on Thursday. CVS Health Corporation has a 12-month low of $58.50 and a 12-month high of $98.43. The company has a market capitalization of $117.41 billion, a price-to-earnings ratio of 40.54, a price-to-earnings-growth ratio of 0.89 and a beta of 0.60. The company has a debt-to-equity ratio of 0.78, a current ratio of 0.87 and a quick ratio of 0.66. The firm’s fifty day moving average price is $81.35 and its 200 day moving average price is $79.37.

CVS Health (NYSE:CVS) last released its quarterly earnings results on Wednesday, May 6th. The pharmacy operator reported $2.57 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.21 by $0.36. The firm had revenue of $100.43 billion for the quarter, compared to the consensus estimate of $94.99 billion. CVS Health had a net margin of 0.72% and a return on equity of 11.88%. The firm’s quarterly revenue was up 6.2% on a year-over-year basis. During the same quarter in the previous year, the firm posted $2.25 EPS. CVS Health has set its FY 2026 guidance at 7.300-7.500 EPS. On average, research analysts forecast that CVS Health Corporation will post 7.44 EPS for the current fiscal year.

CVS Health Announces Dividend

The business also recently announced a quarterly dividend, which was paid on Monday, May 4th. Stockholders of record on Thursday, April 23rd were given a $0.665 dividend. The ex-dividend date of this dividend was Thursday, April 23rd. This represents a $2.66 annualized dividend and a dividend yield of 2.9%. CVS Health’s payout ratio is presently 117.18%.

Wall Street Analysts Forecast Growth

Several equities analysts recently weighed in on CVS shares. Royal Bank Of Canada lifted their target price on shares of CVS Health from $93.00 to $107.00 and gave the company an “outperform” rating in a report on Thursday, May 7th. HSBC lifted their price target on shares of CVS Health from $83.00 to $85.00 and gave the stock a “hold” rating in a research note on Tuesday, May 5th. Piper Sandler dropped their price target on shares of CVS Health from $101.00 to $99.00 and set an “overweight” rating on the stock in a research note on Tuesday, March 31st. Leerink Partners reaffirmed an “outperform” rating and set a $98.00 price target on shares of CVS Health in a research note on Thursday, March 5th. Finally, JPMorgan Chase & Co. lifted their price target on shares of CVS Health from $101.00 to $111.00 and gave the stock an “overweight” rating in a research note on Tuesday, May 12th. Twenty-two research analysts have rated the stock with a Buy rating and four have issued a Hold rating to the stock. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average price target of $98.88.

CVS Health Company Profile

CVS Health Corporation is a diversified healthcare company that operates a large network of retail pharmacies, pharmacy benefit management services and health care solutions. Headquartered in Woonsocket, Rhode Island, the company traces its roots to the early 1960s and has grown into an integrated provider of prescription drugs, over?the?counter products, clinical services and health insurance offerings. Its operating model combines retail pharmacy locations and in?store clinics with broader pharmacy and health plan capabilities.

Key business activities include CVS Pharmacy retail operations, MinuteClinic walk?in medical clinics and HealthHUB locations that offer expanded clinical services.